ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag business biobusiness tuberculosis pharma genetics genomics

23andMe Enters Drug Development
Kerry Grens | Mar 12, 2015 | 2 min read
The personal genomics firm announces plans to make medicines.
The Growth of Iowa Biotech
Jenny Rood | Aug 1, 2016 | 7 min read
The state’s industry draws inspiration from medicine as well as agriculture.
Researchers in George Church&rsquo;s lab modified wild type ADK proteins (left) in <em >E.coli</em>, furnishing them with an nonstandard amino acid (nsAA) meant to biocontain the resulting bacterial strain.
A Pioneer of The Multiplex Frontier
Rashmi Shivni, Drug Discovery News | May 20, 2023 | 10 min read
George Church is at it again, this time using multiplex gene editing to create virus-proof cells, improve organ transplant success, and protect elephants.
Brain cells with electrical firing. 3D rendering.
Microglia as Therapeutic Targets in Neurodegenerative Diseases
Sruthi S. Balakrishnan | Oct 1, 2021 | 10+ min read
Pharmaceutical companies ramp up efforts to get the brain’s immune cells to help treat Alzheimer’s disease and other conditions, but not everyone agrees the approach will be effective.
Natural Killer Cell Therapies Catch Up to CAR T
Bianca Nogrady | Apr 1, 2020 | 8 min read
There’s a new cell-based cancer immunotherapy on the block.
Sequencing Stakes: Celera Genomics Carves Its Niche
Ricki Lewis | Jul 18, 1999 | 8 min read
J. Craig Venter is no stranger to contradiction and controversy. He seems to thrive on it. In 1991, when the National Institutes of Health was haggling over patenting expressed sequence tags (ESTs)--a shortcut to identifying protein-encoding genes--Venter the inventor accepted a private offer to found The Institute for Genomic Research (TIGR) in Rockville, Md. TIGR would discover ESTs and give most of them to a commercial sibling, Human Genome Sciences (HGS), to market. ESTs are now a standard
A Flood in Genomics
Brendan Maher | Nov 25, 2001 | 9 min read
Nine months have passed since draft sequences of the human genome were first published.1,2 One human gestation period later, the genome, as deciphered by the International Human Genome Sequencing Consortium, still screams toward its projected Spring 2003 finish date. "The trajectory we're on for meeting that goal is precisely on target," assures Francis Collins, director, National Human Genome Research Institute (NHGRI) and spokesperson for the largest public biological science project in histor
Making Money from the Interactome
Kate Fodor | Mar 1, 2006 | 3 min read
FEATUREHuman Interactome Project Making Money from the InteractomeBY KATE FODOR© THOM GRAVESAs companies consider their roles in the massive human interactome project, they are keeping in mind some hard-learned lessons. Chief among their case studies is Celera Genomics, which proved that databases cannot, per se, be a firm's main revenue source. "Companies don't talk anymore about the raw data they can amass fo
Differential Gene Expression: Technology Provides Quick Access to DNA Data
James Kling | Aug 30, 1998 | 6 min read
HOW IT WORKS: This diagram shows how Genzyme's SAGE method flows from one stage to another. In 1997, Genzyme Corp. of Cambridge, Mass., was shopping for new technology. "We were creating a cancer company, to put together a group of technologies that would give us a gene-based approach to cancer drug discovery," recalls Susan Primrose, director of business development at the now-formed Genzyme Molecular Oncology (GMO) in Framingham, Mass. They found a key to their project in SAGE (Serial Anal
Clinton, Blair Stoke Debate on Gene Data
Ricki Lewis | Apr 2, 2000 | 7 min read
President Bill Clinton and British Prime Minister Tony Blair's brief statement of March 14 supporting free access to human genome information unleashed a slew of clichés, including "too little too late" and "water under the bridge." But initial misinterpretation of the statement led to a temporary slide in biotech stocks. By the end of the day, Celera Genomics Corp. of Rockville, Md., had dropped 19 percent, while Incyte Pharmaceuticals of Palo Alto, Calif., plummeted 27 percent. Even thoug

Run a Search

ADVERTISEMENT